Close

Exelixis (EXEL) Announces Cabozantinib Phase 3 Met Primary Endpont vs. Everolimus in RCC

July 20, 2015 7:01 AM EDT Send to a Friend
Exelixis (NASDAQ: EXEL) announced positive top-line results from the primary analysis of METEOR, the phase 3 pivotal trial comparing cabozantinib ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login